Navigation Links
Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
Date:2/21/2008

than prescription growth primarily due to restocking to normal levels in 2007 and the impact of price increases in November 2006 and August 2007.

LIALDA/MEZAVANT - Ulcerative colitis

Shire launched LIALDA in the US oral mesalamine market in March 2007, and by December 31, 2007 LIALDA had reached a market share of 8.0% (average annual market share 3.9%). LIALDA's product sales for the year to December 31, 2007 were $50.5 million. All initial launch stocks of LIALDA totaling $34.7 million were recognised into revenue during the year to December 31, 2007.

The product was launched in the UK in November 2007, Canada in January 2008 and further launches are planned in the EU during 2008, subject to the successful conclusion of pricing and reimbursement negotiations. In the UK and Ireland the product will be called MEZAVANT XL and Shire plans to market the product in most other EU countries as MEZAVANT.

Since the launch of LIALDA in March 2007, PENTASA and LIALDA's combined share of the US oral mesalamine prescription market had grown to 24.9% as at December 31, 2007, up from 17.6% as at December 31, 2006.

FOSRENOL - Hyperphosphatemia

FOSRENOL is now available in 24 countries and global sales totaled $102.2 million for the year to December 31, 2007 (2006: $44.8 million). Outside the US, FOSRENOL has now been launched in Germany, France, UK, Italy and Spain (in January 2008) and a number of other countries. Sales of FOSRENOL outside the US for the year ended December 31, 2007 were $40.1 million (2006: $4.6 million).

US sales of FOSRENOL for the year to December 31, 2007 were up 54% to $62.1 million compared to the same period in 2006 (2006: $40.2 million). FOSRENOL's average market share of the US phosphate binder market increased from 8.5% in 2006 to 8.6% in 2007. The increase in product sales is due to a small wholesaler stocking increase in 2007 compared to significant wholesaler de-stocking of initial launch stocks in 200
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Correction Re Website
2. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
3. Shire Engages Palio
4. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
5. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
6. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire plc: Board Changes
9. David Mott Appointed Non Executive Director at Shire
10. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
11. Shire Divests Non-Core Product Portfolio to Almirall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... / Rootstown, OH (PRWEB) January 22, 2015 ... platform, announced today that it has received AOAC-PTM Certifications for ... O1O3, O111, O121, and O145; collectively referred to as STEC ... O157, at 1 colony forming unit (cfu) per 325 g ...
(Date:1/22/2015)... DE (PRWEB) January 22, 2015 Controlled ... Pistoia Alliance, which helps companies check the legal requirements ... to expand to China. , As their international ... are globally adopting software solutions built as a result ...
(Date:1/22/2015)... 2015   Cypher Genomics, Inc., the leading ... SQNM ), the leading molecular diagnostics company, ... noninvasive prenatal tests (NIPT). Through this agreement, Sequenom ... to advance analysis of clinically-relevant fetal sub-chromosomal variants ...
(Date:12/25/2014)... report “Service Quality Management and Telco Customer Experience Management ... Advancements, Worldwide Forecasts & Analysis (2014-2019)” defines and segments ... revenues. , Browse 152 market data tables, 19 ... “Service Quality Management (SQM) and Telco Customer Experience Management ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Global Compliance Service for Controlled Substances to Expand to China 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4
... Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced its financial results,and ... 31, 2008., "We are currently enrolling or ... four exploring the use of REOLYSIN(R) as a ... combination with a variety of,chemotherapies, immune modulation and ...
... batch of bluetongue Bovilis BTV8 vaccine released to supply Northern ... ... Animal Health (NYSE: SGP ) released the first batch,of Bovilis ... company, combining after the acquisition in 2007 the,strength of Intervet and ...
... BOSTON, April 30 Today John C. Lechleiter,Ph.D., ... (NYSE: LLY ), provided,insight into the future ... that,key players, significant investments in the sector are ... Conference, a gathering of,policymakers, business leaders and academics, ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces 2008 First Quarter Results 2Oncolytics Biotech Inc. Announces 2008 First Quarter Results 3Oncolytics Biotech Inc. Announces 2008 First Quarter Results 4Oncolytics Biotech Inc. Announces 2008 First Quarter Results 5Oncolytics Biotech Inc. Announces 2008 First Quarter Results 6Oncolytics Biotech Inc. Announces 2008 First Quarter Results 7Oncolytics Biotech Inc. Announces 2008 First Quarter Results 8Oncolytics Biotech Inc. Announces 2008 First Quarter Results 9Oncolytics Biotech Inc. Announces 2008 First Quarter Results 10Oncolytics Biotech Inc. Announces 2008 First Quarter Results 11Oncolytics Biotech Inc. Announces 2008 First Quarter Results 12Oncolytics Biotech Inc. Announces 2008 First Quarter Results 13Oncolytics Biotech Inc. Announces 2008 First Quarter Results 14Oncolytics Biotech Inc. Announces 2008 First Quarter Results 15Oncolytics Biotech Inc. Announces 2008 First Quarter Results 16Oncolytics Biotech Inc. Announces 2008 First Quarter Results 17Oncolytics Biotech Inc. Announces 2008 First Quarter Results 18Oncolytics Biotech Inc. Announces 2008 First Quarter Results 19Oncolytics Biotech Inc. Announces 2008 First Quarter Results 20Oncolytics Biotech Inc. Announces 2008 First Quarter Results 21Oncolytics Biotech Inc. Announces 2008 First Quarter Results 22Oncolytics Biotech Inc. Announces 2008 First Quarter Results 23Oncolytics Biotech Inc. Announces 2008 First Quarter Results 24Oncolytics Biotech Inc. Announces 2008 First Quarter Results 25Oncolytics Biotech Inc. Announces 2008 First Quarter Results 26Oncolytics Biotech Inc. Announces 2008 First Quarter Results 27Oncolytics Biotech Inc. Announces 2008 First Quarter Results 28Oncolytics Biotech Inc. Announces 2008 First Quarter Results 29Oncolytics Biotech Inc. Announces 2008 First Quarter Results 30Oncolytics Biotech Inc. Announces 2008 First Quarter Results 31Oncolytics Biotech Inc. Announces 2008 First Quarter Results 32Oncolytics Biotech Inc. Announces 2008 First Quarter Results 33Intervet/Schering-Plough Animal Health Outlines Strength of the Combination 2Intervet/Schering-Plough Animal Health Outlines Strength of the Combination 3Lilly CEO Urges Policy Prescriptions to Help Ensure Public and Private Biotech Investments Generate Dividends and U.S. Job Growth 2
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ... "The Global Watermarking and Fingerprinting Markets" report ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides an ... fingerprinting markets. Watermarking aims to control and monitor ...
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ... Monitor: North America Perimeter Security Systems Market" report to ... The North American perimeter security market is estimated to ... Although the U.S. market holds a larger share in this ...
(Date:12/17/2014)... DUBLIN , Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home Button ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first time ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... Analysis of a rock type found only in the world,s ... first got a foothold on the Earth. , A scientific ... Copenhagen in Denmark, and including scientists from Newcastle University, UK, ... first time managed to plot the rise and fall of ...
... 2,000 or so years since the Roman Empire employed ... vast system of concrete aqueducts and other large edifices, ... and created entirely new building materials such as steel, ... scale. Oddly enough, the three-dimensional crystalline structure ...
... Moscone Center will play host to one of the world,s ... Agents and Chemotherapy (ICAAC). From September 12-15, nearly 8,000 ... 11,000 people. ICAAC has traditionally been an outlet for ... drugs. Among the announcements expected next week: ...
Cached Biology News:Ancient oceans offer new insight into the origins of animal life 2Cement's basic molecular structure finally decoded 2Cement's basic molecular structure finally decoded 3
GM130 Immunogen: Recombinant purified rat GM130 Family / Subclass 1: Signal Transduction Storage: 4 C...
NATIVE RAT OSTEOCALCIN...
... Specifications(L x W x H): 17 ... 5/16"18.7 lbsCapacity: 12 slidesTime: Programmable 0 - ... denaturation and hybridization steps 40 user programmable ... and Fixed temperature) Rapid temperature ramp-up from ...
Defender against cell death 1...
Biology Products: